Vyant Bio, Inc.
VYNTDelisted May 4, 2023- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001349929
Vyant Bio, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 17 institutions reported holding it in 13F filings for Q1 2023, worth $136.8K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 17
- Q1 2023, 0 vs. previous quarter
- 13F value
- $136.8K
- Reported value at the end of Q1 2023
- Superinvestors holding
- 0
- At the end of Q1 2023
Superinvestors holding VYNT, Q1 2023
No superinvestor reported holding VYNT at the end of Q1 2023.
Latest insider trades
Open-market purchases and sales by Vyant Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 22, 2022 (view filing) | Nov 18 | 4 days | Harris Geoffrey E.Director | SSaleCommon Stock, $0.0001 par value | −765 | $1.33 | −$1.02K | −5.2%14.0K after | 2 lots |
| Dec 29, 2021 (view filing) | Nov 23 | 36 days | LaFrence Andrew D.C.Chief Financial Officer | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $2.00 | +$10.0K | +17.1%34.3K after | Amended |
| Dec 7, 2021 (view filing) | Dec 6 | 1 day | Boehm MarcusDirector | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $1.69 | +$8.45K | +4.0%128.8K after | |
| Nov 24, 2021 (view filing) | Nov 24 | Same day | Roberts John AChief Executive Officer | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $2.02 | +$10.1K | +14.4%39.8K after | |
| Nov 23, 2021 (view filing) | Nov 22 | 1 day | Yeh Yung-PingChief Innovation Officer | PPurchaseCommon Stock, $0.0001 par value | +500 | $2.05 | +$1.02K | +4.1%12.8K after | |
| Nov 17, 2021 (view filing) | Oct 28 | 20 daysLate | Fremeau Robert Thomas Jr.Chief Scientific Officer | PPurchaseCommon Stock, $0.0001 par value | +1.00K | $2.19 | +$2.19K | New position1.00K after | |
| Oct 28, 2021 (view filing) | Oct 27 | 1 day | Boehm MarcusDirector | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $2.10 | +$10.5K | +4.2%123.8K after | |
| Sep 30, 2021 (view filing) | Sep 29 | 1 day | Boehm MarcusDirector | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $2.44 | +$12.2K | +4.4%118.8K after | |
| Aug 27, 2021 (view filing) | Aug 25 | 2 days | Yeh Yung-PingChief Innovation Officer | PPurchaseCommon Stock, $0.0001 par value | +1.00K | $2.64 | +$2.64K | +8.9%12.3K after | |
| Aug 26, 2021 (view filing) | Aug 25 | 1 day | Boehm MarcusDirector | PPurchaseCommon Stock, $0.0001 par value | +5.00K | $2.58 | +$12.9K | +4.6%113.8K after |
Top 10 13F holders, Q1 2023
The largest institutional positions in Vyant Bio, Inc. at the end of Q1 2023; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 47,256 | $27.4K | 0.00% | −98,463−67.6% | Reduced |
| Geode Capital Management, LLC | 38,820 | $22.5K | 0.00% | 00.0% | Unchanged |
| Mayo Clinic | 27,742 | $16.1K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 26,558 | $15.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 22,419 | $13.0K | 0.00% | +22,419 | New |
| Susquehanna International Group, LLP | 20,001 | $11.6K | 0.00% | +20,001 | New |
| State Street Corp | 15,038 | $8.72K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,820 | $8.00K | 0.00% | −500−3.5% | Reduced |
| Virtu Financial LLC | 12,521 | $7.00K | 0.00% | +953+8.2% | Added |
| UBS Group AG | 5,463 | $3.17K | 0.00% | +508+10.3% | Added |